# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-26-171799
Filing Date
2026-04-23
Accepted
2026-04-23 07:00:34
Documents
16
Period of Report
2026-06-03

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | d113727ddef14a.htm iXBRL | DEF 14A | 592707
3 | GRAPHIC | g113727g16w01.jpg | GRAPHIC | 250937
4 | GRAPHIC | g113727g16w02.jpg | GRAPHIC | 229627
5 | GRAPHIC | g113727g47x01.jpg | GRAPHIC | 133186
6 | GRAPHIC | g113727g47x02.jpg | GRAPHIC | 136243
| Complete submission text file | 0001193125-26-171799.txt |  | 3098182

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
2 | XBRL TAXONOMY EXTENSION SCHEMA | nerv-20251231.xsd | EX-101.SCH | 11381
21 | EXTRACTED XBRL INSTANCE DOCUMENT | d113727ddef14a_htm.xml | XML | 147696

Mailing Address 1500 DISTRICT AVENUE BURLINGTON MA 01803
Business Address 1500 DISTRICT AVENUE BURLINGTON MA 01803 617-600-7373
Minerva Neurosciences, Inc. (Filer) CIK: 0001598646 (see all company filings)

EIN.: 260784194 | State of Incorp.: MA | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36517 | Film No.: 26885480
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)